Loading...
•
Dec 31, 2020
Zai Lab Q4 2020 Earnings Report
Zai Lab reported financial results for the second half and full year of 2020 and provided corporate updates.
Key Takeaways
Zai Lab reported full-year 2020 revenues of $49.0 million, driven by sales of ZEJULA and Optune. The company highlighted key achievements including the inclusion of ZEJULA in the NRDL and progress in clinical development with multiple product candidates.
ZEJULA was successfully launched for both second-line and first-line ovarian cancer and Optune for glioblastoma in China.
NDAs were submitted and granted priority reviews by China’s NMPA for QINLOCK and NUZYRA.
The company expanded its pipeline through new strategic partnerships, increasing the total product candidates to 21.
ZEJULA for second-line ovarian cancer has been included in the National Reimbursement Drug List (NRDL).
Zai Lab
Zai Lab
Zai Lab Revenue by Segment
Revenue by Segment
ZEJULA Revenue
CapyFin.com Forward Guidance
Zai Lab expects to receive approval for and launch QINLOCK and NUZYRA in China in 2021 and plans to submit regulatory filings for Tumor Treating Fields in mesothelioma and for MARGENZA in HER2-positive breast cancer in China.
Positive Outlook
- Potential approval and launch of QINLOCK in China.
- Potential approval and launch of NUZYRA in China.
- ZEJULA included in the National Reimbursement Drug List (NRDL) will drive strong volume growth.
- Submission of regulatory filings for Tumor Treating Fields in mesothelioma in China.
- Submission of regulatory filings for MARGENZA in HER2-positive breast cancer in China.